Exploratory Study of ADR-002K for Heart Failure Patients with Ischemic Heart Disease who Undergo Coronary Artery Bypass Surgery

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2053250022

Enrollment

Registered

2025-05-14

Start date

2025-05-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure Patients with Ischemic Heart Disease who Undergo Coronary Artery Bypass Surgery Coronary Artery Bypass Surgery, Ischemic Heart Disease, Adipose-derived Mesenchymal Stem Cells

Interventions

Coronary Artery Bypass Surgery, ADR-002K

D045164

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who are clinically diagnosed heart failure with ischemic heart disease and receive CABG 2) Patients with a left ventricular ejection fraction of 40% or less before CABG 3) Others

Exclusion criteria

Exclusion criteria: 1) Patients who have a combination of cardiovascular disease such as severe organic valvular disease 2) Patients whose participation in a clinical trial is considered inappropriate at the discretion of the investigator or co-investigator 3) Others

Design outcomes

Primary

Measure	Time frame
Heart Failure Event	—

Secondary

Measure	Time frame
1) Cardiac Function 2) QOL 3) Others	—

Contacts

Public ContactToshiyuki Osawa

ROHTO Pharmaceutical Co., Ltd.

R-regenerative_medicine@rohto.co.jp+81-6-6447-8610

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026